Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | MAOB | P27338 | 2/20 | 0.68 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | PGR | P06401 | 1/20 | 0.66 |
| ▸ | HTR1A | P08908 | 1/20 | 0.66 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.66 |
| ▸ | MAPT | P10636 | 1/20 | 0.66 |
| ▸ | PDE4A | P27815 | 1/20 | 0.66 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.66 |
| ▸ | DRD3 | P35462 | 1/20 | 0.66 |
| ▸ | SNCA | P37840 | 1/20 | 0.66 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 9/20 | 0.62 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 4/20 | 0.46 |
| ▸ | BACE1 | P56817 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9975753 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL29358434 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q4 SCHEMBL6279408 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL13026488 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL11901691 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Ubidecarenone SCHEMBL19858 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL16393869 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| SCHEMBL5530210 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q4 SCHEMBL6279406 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A | |
| Coenzyme Q6 SCHEMBL29404151 | 1.00 | LMNA (1.00) | LMNAMAOBPTGS1PGRHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | NEW YORK UNIVERSITY (US) | 2026-02-12 | — | — | US | claimed |
| WO-2025231487-A1 | PHOTORECEPTOR SPECIFIC PROMOTORS FOR USE IN GENE THERAPIES FOR TREATMENT OF RETINAL DEGENERATION | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2025-11-06 | — | — | WO | claimed |
| US-20250262169-A1 | METHODS OF TREATING COENZYME Q10 DEFICIENCY | THLIVERIS, ANDREW T. | 2025-08-21 | — | — | US | claimed |
| CN-118531016-B | Nucleic acid molecule, expression cassette, recombinant strain and application thereof | 新开利安生物科技(海南)有限公司 | 2025-04-04 | — | — | CN | claimed |
| CN-119120695-A | Genetic marker, metabolic marker and kit for statin muscle toxicity | 中日友好医院(中日友好临床医学研究所) | 2024-12-13 | — | — | CN | claimed |
| CN-117587128-B | Biomarker combinations and their use in predicting and/or diagnosing colorectal cancer | 上海爱谱蒂康生物科技有限公司 | 2024-10-22 | — | — | CN | claimed |
| CN-118531016-A | Nucleic acid molecule, expression cassette, recombinant strain and application thereof | 新开利安生物科技(海南)有限公司 | 2024-08-23 | — | — | CN | claimed |
| US-12024750-B2 | Methylation markers and targeted methylation probe panel | GRAIL, LLC (US) | 2024-07-02 | — | — | US | claimed |
| CN-117587128-A | Biomarker combinations and their use in predicting and/or diagnosing colorectal cancer | 上海爱谱蒂康生物科技有限公司 | 2024-02-23 | — | — | CN | claimed |
| WO-2024039764-A2 | EPITRANSCRIPTOMIC ANALYSIS OF GLIOMA | OHIO STATE INNOVATION FOUNDATION (US) | 2024-02-22 | — | — | WO | claimed |
| US-20230282308-A1 | Systems-level Analysis of 32 TCGA Cancers Reveals Disease-Dependent tRNA Fragmentation Patterns and Very Selective Associations with Messenger RNAs and Repeat Elements | THOMAS JEFFERSON UNIVERSITY (US) | 2023-09-07 | — | — | US | claimed |
| US-20230193205-A1 | GENE MODIFIED FIBROBLASTS FOR THERAPEUTIC APPLICATIONS | FIGENE, LLC | 2023-06-22 | — | — | US | claimed |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2023-03-23 | — | — | US | claimed |
| US-20220409554-A1 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | IC-MedTech Corp. | 2022-12-29 | — | — | US | claimed |
| US-11485743-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-11-01 | — | — | US | claimed |
| US-20220243273-A1 | BLOOD RNA BIOMARKERS OF CORONARY ARTERY DISEASE | THE GEORGE WASHINGTON UNIVERSITY | 2022-08-04 | — | — | US | claimed |
| US-12636369-B2 | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof | FLAGSHIP PIONEERING INNOVATIONS VI, LLC (US) | 2026-05-26 | — | — | US | disclosed |
| CN-121950947-A | Method for improving content of Antrodia camphorate triterpene compounds by using recombinant yeast methyltransferase | 江西根稷企业管理服务有限公司 | 2026-05-01 | — | — | CN | disclosed |
| US-11285125-B2 | Oxidative retinal diseases | RETROTOPE, INC. (US) | 2022-03-29 | — | — | US | disclosed |
| US-11274281-B2 | Exosomes from clonal progenitor cells | ReCyte Therapeutics, Inc. (US) | 2022-03-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11485743-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | LMNA 2563/4885MAOB 2702/4885PTGS1 4442/4885 |
| US-20230093080-A1 | PROTEIN DEGRADERS AND USES THEREOF | MDM2, CUL1, PSMG3 | LMNA 2563/4885MAOB 2702/4885PTGS1 4442/4885 |
| US-11285125-B2 | Oxidative retinal diseases | ALDH1A2, TXNRD2, STARD3 | LMNA 1713/4885MAOB 2923/4885PTGS1 205/4885 |
| US-20250262169-A1 | METHODS OF TREATING COENZYME Q10 DEFICIENCY | NDUFB10, NDUFA10, NDUFB11 | LMNA 1283/4885MAOB 664/4885PTGS1 1676/4885 |
| US-20260041336-A1 | PLATELET REACTIVITY EXPRESSION SCORE PREDICTS CARDIOVASCULAR RISK | EPB41L2, MYLK2, RABL3 | LMNA 4313/4885MAOB 4087/4885PTGS1 3091/4885 |
| US-12636369-B2 | Compositions comprising circular polyribonucleotides for protein modulation and uses thereof | USP25, RBM25, TRIM25 | LMNA 1111/4885MAOB 4226/4885PTGS1 4262/4885 |
| US-20220409554-A1 | ASCORBIC ACID AND QUINONE COMPOUND FOR CANCER TREATMENT | NQO1, SDHB, SDHA | LMNA 2639/4885MAOB 372/4885PTGS1 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.